FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027806809> ?p ?o ?g. }

• W2027806809 endingPage "52" @default.
• W2027806809 startingPage "45" @default.
• W2027806809 abstract "To date, no standard adjuvant therapy have increased overall survival in patients with malignant melanoma (MM). The effect of interferon alpha as a single agent or in combination has been widely explored in clinical trials. Critical reading of the major international randomised trials showed that response to interferon (IFN) in terms of improvement of overall survival (OS) may not be strictly correlated with the used dosage and that duration of therapy may impact disease-free survival (DFS) but not OS. Patients’ heterogeneity could be an explanation for the discordant data of the international literature. Indeed, majority of these studies started in late 1980s or early 1990s, when accurate staging procedure were not available yet. The adequate surgical treatment should be considered as an independent variable in the analysis of MM adjuvant protocols. Considering the treatment cost, which is the main goal: DFS, OS or quality of life? Answering these questions is difficult, but some considerations must be taken to put order in this field. Putting together data from all different studies, IFN therapy seems to protect MM patients from recurrences during the entire treatment period and a prolonged IFN therapy seems to improve DFS. The only positive result on OS was demonstrated for high-dose IFN (HD-IFN) in a single study (presenting a relatively short follow-up median) and not confirmed in a subsequent study from the same authors. Considering that low-dose interferon (LD-IFN) is tolerated much better than HD-IFN (about 10% versus more than 70% of cases with grade 3–4 toxicity, respectively), a prolonged LD-IFN (more than 2 years) may represent a reasonable opportunity for MM patients, also considering its advantageous cost-effectiveness. Conversely, considering the improvement of OS as the main target of MM adjuvant therapy, the “wait and watch” attitude remains the only approach to be pursued at present. It is a physician's choice." @default.
• W2027806809 created "2016-06-24" @default.
• W2027806809 creator A5008816822 @default.
• W2027806809 creator A5013545527 @default.
• W2027806809 creator A5028542645 @default.
• W2027806809 creator A5029398339 @default.
• W2027806809 creator A5071949598 @default.
• W2027806809 creator A5086592438 @default.
• W2027806809 creator A5089512613 @default.
• W2027806809 date "2006-01-01" @default.
• W2027806809 modified "2023-09-27" @default.
• W2027806809 title "Adjuvant treatment of malignant melanoma: Where are we?" @default.
• W2027806809 cites W134362622 @default.
• W2027806809 cites W1501257267 @default.
• W2027806809 cites W1543229551 @default.
• W2027806809 cites W1819917384 @default.
• W2027806809 cites W1828940258 @default.
• W2027806809 cites W1908752382 @default.
• W2027806809 cites W1911828475 @default.
• W2027806809 cites W1959475812 @default.
• W2027806809 cites W1964478633 @default.
• W2027806809 cites W1965316449 @default.
• W2027806809 cites W1965643834 @default.
• W2027806809 cites W1965972363 @default.
• W2027806809 cites W1966732847 @default.
• W2027806809 cites W1971542900 @default.
• W2027806809 cites W1972512828 @default.
• W2027806809 cites W1975563834 @default.
• W2027806809 cites W1990435553 @default.
• W2027806809 cites W1991692982 @default.
• W2027806809 cites W1993455773 @default.
• W2027806809 cites W2001672065 @default.
• W2027806809 cites W2008527311 @default.
• W2027806809 cites W2009927364 @default.
• W2027806809 cites W2010447712 @default.
• W2027806809 cites W2011184271 @default.
• W2027806809 cites W2013259535 @default.
• W2027806809 cites W2015436210 @default.
• W2027806809 cites W2033166860 @default.
• W2027806809 cites W2033172381 @default.
• W2027806809 cites W2055084054 @default.
• W2027806809 cites W2060662007 @default.
• W2027806809 cites W2070520491 @default.
• W2027806809 cites W2078288681 @default.
• W2027806809 cites W2090324800 @default.
• W2027806809 cites W2092794098 @default.
• W2027806809 cites W2096137749 @default.
• W2027806809 cites W2097747927 @default.
• W2027806809 cites W2098867430 @default.
• W2027806809 cites W2108125679 @default.
• W2027806809 cites W2110076708 @default.
• W2027806809 cites W2114054629 @default.
• W2027806809 cites W2118449798 @default.
• W2027806809 cites W2131772284 @default.
• W2027806809 cites W2137978694 @default.
• W2027806809 cites W2143422545 @default.
• W2027806809 cites W2143923888 @default.
• W2027806809 cites W2168593612 @default.
• W2027806809 cites W2181690957 @default.
• W2027806809 cites W2231116265 @default.
• W2027806809 cites W2312728647 @default.
• W2027806809 cites W2408675770 @default.
• W2027806809 cites W2412565307 @default.
• W2027806809 cites W2415420478 @default.
• W2027806809 cites W87169064 @default.
• W2027806809 cites W1795798219 @default.
• W2027806809 doi "https://doi.org/10.1016/j.critrevonc.2005.05.002" @default.
• W2027806809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15990330" @default.
• W2027806809 hasPublicationYear "2006" @default.
• W2027806809 type Work @default.
• W2027806809 sameAs 2027806809 @default.
• W2027806809 citedByCount "8" @default.
• W2027806809 crossrefType "journal-article" @default.
• W2027806809 hasAuthorship W2027806809A5008816822 @default.
• W2027806809 hasAuthorship W2027806809A5013545527 @default.
• W2027806809 hasAuthorship W2027806809A5028542645 @default.
• W2027806809 hasAuthorship W2027806809A5029398339 @default.
• W2027806809 hasAuthorship W2027806809A5071949598 @default.
• W2027806809 hasAuthorship W2027806809A5086592438 @default.
• W2027806809 hasAuthorship W2027806809A5089512613 @default.
• W2027806809 hasConcept C126322002 @default.
• W2027806809 hasConcept C141071460 @default.
• W2027806809 hasConcept C143998085 @default.
• W2027806809 hasConcept C203014093 @default.
• W2027806809 hasConcept C2776178377 @default.
• W2027806809 hasConcept C2776694085 @default.
• W2027806809 hasConcept C2777658100 @default.
• W2027806809 hasConcept C2777863537 @default.
• W2027806809 hasConcept C2777982462 @default.
• W2027806809 hasConcept C2781228144 @default.
• W2027806809 hasConcept C2909179924 @default.
• W2027806809 hasConcept C502942594 @default.
• W2027806809 hasConcept C535046627 @default.
• W2027806809 hasConcept C71924100 @default.
• W2027806809 hasConceptScore W2027806809C126322002 @default.
• W2027806809 hasConceptScore W2027806809C141071460 @default.
• W2027806809 hasConceptScore W2027806809C143998085 @default.
• W2027806809 hasConceptScore W2027806809C203014093 @default.

• next